BioAtla https://validator.w3.org/feed/docs/rss2.html Home T-cell Engager in Patients with Treatment Refractory Metastatic Adenocarcinoma Targeting HPV E6/E7 Upregulation of ROR2 with Oz-V in OPSCC First-in-Human Phase 1 Study of a Dual-Conditionally Active Biologic (CAB) EpCAM x CD3 Bispecific T-cell Engager (TCE), BA3182, in Patients with Treatment Refractory Metastatic Adenocarcinoma Preliminary Results from a First-in-Human Phase 1 Study of a Dual-Conditionally Binding CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager, BA3182, in Patients with Treatment Refractory Metastatic Adenocarcinoma Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC Updated Results from a Study of Evalstotug (BA3071), an Anti–CTLA-4 Conditionally Active Biologic Exploratory Analysis of Overall Survival among Non-Small Cell Lung Cancer (NSCLC) Patients with Mutated KRAS in a Phase 2 Trial of Mecbotamab Vedotin (CAB-AXL-ADC) Identification of novel senolytic targets and development of Conditionally Active Biologic-based-drug conjugates for targeted senescence-associated secretory phenotype elimination in vivo About Us Ozuriftamab Vedotin (BA3021), a Conditionally Binding ROR2-ADC in Patients with Heavily Pretreated Squamous Cell Carcinoma of the Head and Neck: Antitumor Activity Observed Among Patients with Both HPV Related and HPV-Negative Cancers Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody–drug conjugate BA3361, A Tumor Selective, Conditionally Active anti-Nectin4 ADC with a Novel NextGen Linker System has improved Efficacy in Pancreatic Cancer Models Interim Safety and Efficacy Results from Phase 1/2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in Patients with Advanced Sarcoma Updated Phase 1 and preliminary Phase 2 results from a study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC BA3361, a NextGen CAB ADC Targeting Nectin4 Phase 2 Trial of Ozuriftamab Vedotin (Oz-V), a Conditionally Binding CAB-ROR2-ADC, in Patients with Heavily Pretreated Squamous Cell Carcinoma A Novel Conditional Active Biologic Anti-EpCAM x Anti-CD3 Bispecific Antibody with Synergistic Tumor Selectivity for Cancer Immunotherapy Conditionally Active Biologics<sup>™</sup> (CAB) Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches Strategic Relationships Results from a Phase 2 Part 1 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in Patients with Advanced Refractory Sarcoma Novel Conditionally Active Biologic Tetravalent T-Cell Engagers Targeting Solid Tumors Scientific Glossary Phase 1 Study of Evalstotug (BA3071), an anti–CTLA-4 Conditionally Active Biologic, in Combination with Nivolumab in Advanced Solid Tumors Conditionally Active Biologics Eliminate Senescence Cells in Cancer and Aging Novel Conditionally Active Tetravalent B7-H3 x CD3 T-cell Engagers Targeting Solid Tumors Conditionally Active Biologics Targeting Novel Senescence Markers Effectively Eliminate the Senescence-Associated Secretory Phenotype in both In Vitro and in Vivo Models Expanded Access Policy A Novel Dual CAB Nectin-4 x CD3 Bispecific Antibody Targeting Solid Tumors A Novel Dual-Cab Nectin-4 X CD3 Bispecific Antibody Targeting Solid Tumors A Novel Conditionally Active Bispecific HER2 X CD-3 T Cell Engager Targeting Solid Tumors Development of A Humanized Anti-IL-22 Antibody for Cancer and Inflammation Therapy Conditionally Active Biologic (CAB) ADCs with Novel NextGen Linker Show Improved Efficacy and Safety First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC Evalstotug (BA3071): A potent conditionally active biologic (CAB) anti–CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity. Contact Population Pharmacokinetic and Exposure-Response Safety Analyses of Mecbotamab Vedotin (BA3011) in Patients with Advanced Solid Tumors CAB Portfolio Cookie Policy Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety Novel Conditionally Active Bispecific HER2 X CD3 T-Cell Engager Targeting Solid Tumors Appendix NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety A Phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL antibody drug conjugate Publications